The Supreme Court has temporarily blocked a lower court order that would have severely curtailed mail access to mifepristone, the abortion drug at the center of an escalating legal fight over FDA authority and reproductive rights.
Justice Samuel A. Alito Jr. issued the pause on Monday, preventing enforcement of a federal appeals court decision that sought to restrict how the medication could be distributed through the mail. The temporary hold remains in effect at least through Thursday, giving the Supreme Court time to consider whether to intervene more broadly in the case.
The move represents another chapter in the ongoing litigation surrounding mifepristone, which the FDA approved for medication abortion more than two decades ago. The drug regimen has become increasingly central to abortion access as states move to ban or severely limit surgical procedures.
Legal challenges to the drug's approval have mounted since the Supreme Court eliminated the federal constitutional right to abortion last year. Conservative groups and Republican-led states have argued that the FDA acted improperly when it expanded access rules for mifepristone, particularly regarding mail delivery and the number of pills required per dose.
The temporary freeze now in place keeps the current FDA protocol intact for at least the next few days, maintaining the status quo on availability while higher courts evaluate the deeper questions about government regulatory power and access to the drug.
Author Sarah Mitchell: "This is a holding pattern that masks a much larger conflict over who gets to decide abortion access in America, and the clock is already running."
Comments